Genmab — November 2017
-
Amsterdam Vandalismus
-
Amsterdam vandt
-
Lyder godt
-
Ser lige, at der jo også er et fase 2-studie med dara+CyBorD i frontline og 2. linje som skulle have data allerede til februar. Med 36 udelukkende amerikanske lokationer. https://www.clinicaltrials.gov/ct2/show/study/NCT02951819?term=daratumumab+cybord&rank=3#locn
-
Ja, man skal ikke undervurdere prisspørgsmålet i fremtiden. Og når Velcade's patent udløber i 19 i europa, så får dette marked en meget billig 4-kombi - om alt går vel. Der kører et tilsvarende irsk studie - dog kun fase 1 - som har data med på ash.
the only positive i have found so far from Brexit
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind